How Biotech ETFs Are Weathering the Coronavirus Storm
How Biotech ETFs Are Weathering the Coronavirus Storm
While much of the stock market has suffered over the past few weeks thanks to fear of the new coronavirus and its global economic fallout, there are a handful of stocks and exchange traded-funds that have managed to avoid damage, and even flourish.
On this coronavirus-themed episode of Trillions, Bloomberg Intelligence Senior ETF Analyst Eric Balchunas and Bloomberg Businessweek Editor Joel Weber dive into the world of niche biotech ETFs.
Joining them are Paul Yook and Ryan Cinalli of LifeSci Index Partners, who have launched Virtus LifeSci Biotech Product ETF and Virtus LifeSci Biotech Clinical Trials ETF, and are currently working on a third.
To contact the editor responsible for this story: David Rovella at drovella@bloomberg.net, Magnus Henriksson
©2020 Bloomberg L.P.